Diabetes and heart failure patients often treated with diabetes medications considered unsafe

July 15, 2003

In a national study of diabetic patients hospitalized with heart failure, researchers from Yale University and Denver Health Medical Center found that more than a quarter are treated with diabetes medications not considered safe by the United States Food and Drug Administration (FDA).

Published in the July 2 issue of the Journal of the American Medical Association, the study showed that two popular types of diabetes medications-metformin and thiazolidinediones-are frequently used in patients with both diabetes and heart failure despite warnings against their use in this context. Metformin (Glucophage) is not recommended in patients requiring treatment for heart failure because such patients may be particularly susceptible to a serious condition called lactic acidosis.

Thiazolidinediones (Avandia or Actos) are not recommended for patients with significant heart failure symptoms because they may cause fluid retention and worsen symptoms. These warnings, approved by the FDA, are included in the package inserts for these medications.

Using data from the National Heart Care/National Heart Failure Project, a Centers for Medicare & Medicaid Services initiative to improve the care of Medicare patients hospitalized for heart failure between 1998 and 2001, the investigators studied the treatment of diabetes in more than 25,000 patients with heart failure. The researchers found that metformin or thiazolidinediones were prescribed to 13.5 percent of the patients in 1998-99. This practice nearly doubled-to 24.4 percent of patients-by 2000-01.

"The reasons for current patterns of treatment demonstrated in this study are unclear," said senior author Harlan Krumholz, professor of medicine and director of the Yale-New Haven Hospital Center for Outcomes Research and Evaluation. "While it is possible that this practice reflects inadequate knowledge of the potential side-effects of these drugs, it is also possible that some physicians believe that the potential benefits outweigh the potential risks, despite the FDA warnings-and these physicians could be right."

Frederick Masoudi, assistant professor of medicine at Denver Health Medical Center and the University of Colorado Health Sciences Center, and lead author on the study, said, "This study identifies a striking discordance between recommendations from the FDA and current practice patterns for the treatment of diabetes in patients with heart failure nationwide. Furthermore, the use of these drugs has increased dramatically over a relatively short period of time."

Masoudi said that this study highlights the need for further data on the safety of using metformin and thiazolidinediones in patients with heart failure. "Additional research is urgently needed to determine whether this practice is safe. Until such data are available, physicians must either act contrary to the FDA recommendations or have fewer options for the effective treatment of diabetes in patients with heart failure."

Although the care of patients with heart failure has been examined extensively, this study is one of the first to assess the approach to the care of conditions that commonly occur along with heart failure such as diabetes.

"Our findings have important implications for future research efforts," said Krumholz. "A national surveillance system based upon large databases such as that used for this study could be helpful in assessing other patterns of care relevant to patient safety."
-end-
Study authors include Masoudi, Krumholz, Yongfei Wang, statistical analyst, Yale University; Silvio Inzucchi, associate professor of medicine, Yale University; John Setaro, associate professor of medicine, Yale University, Edward Havranek, associate professor of medicine, Denver Health Medical Center and the University of Colorado Health Sciences Center; and JoAnne Foody, assistant professor of medicine, Yale University.

Yale University

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.